GenMark Diagnostics, Inc (GNMK)

Etorro trading 970x250
GenMark Diagnostics, Inc (GNMK) Logo

About GenMark Diagnostics, Inc

GenMark Diagnostics, Inc., a molecular diagnostics company, engages in the developing and commercializing molecular panels based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company also offers Blood Culture Identification Gram-Positive and Negative panel, Blood Culture Identification Fungal Pathogen panel, and ePlex Gastrointestinal Pathogen Panel. In addition, it provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents to support a range of molecular tests with a workstation and disposable test cartridges. Further, the company offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, thrombophilia risk test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test and eSensor SARS-CoV-2 Test. GenMark Diagnostics, Inc. sells its products through direct sales and technically specialized service organization in the United States, Europe, and internationally. The company was incorporated in 2010 and is headquartered in Carlsbad, California. Address: 5964 La Place Court, Carlsbad, CA, United States, 92008-8829

GenMark Diagnostics, Inc News and around…

Latest news about GenMark Diagnostics, Inc (GNMK) common stock and company :

Shares in pharma giant Roche rise as COVID-19 tests offset drug sales slump
21 Apr, 2021 FinancialContent

Demand for healthcare giant Roche’s COVID-19 tests helped to offset a decline in the core drugs business, the company said on Wednesday, as it reported sales for the first quarter of 2021 and confirmed its outlook for the year.

INVESTIGATION ALERT: Halper Sadeh LLP Investigates CLGX, KSHB, AEGN, GNMK; Shareholders Are Encouraged to Contact the Firm
12 Apr, 2021 FinancialContent
INVESTIGATION ALERT: Halper Sadeh LLP Investigates MLND, KSHB, GNMK, ALXN; Shareholders are Encouraged to Contact the Firm
06 Apr, 2021 FinancialContent
INVESTIGATION ALERT: Halper Sadeh LLP Investigates TPCO, GNMK, FI, INSW; Shareholders Are Encouraged to Contact the Firm
05 Apr, 2021 FinancialContent
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates TPCO, DSSI, GNMK, BMTC; Shareholders are Encouraged to Contact the Firm
01 Apr, 2021 FinancialContent
GENMARK ALERT: Bragar Eagel & Squire, P.C. Investigates Recently Announced Tender Offer for GNMK and Encourages Investors to Contact the Firm
31 Mar, 2021 FinancialContent
Why Fulgent Genetics Is a Great Stock to Buy Right Now
31 Mar, 2021 FinancialContent

Shareholders could be big winners if the demand for COVID-19 testing lingers.

Stocks That Hit 52-Week Highs On Friday
26 Mar, 2021 FinancialContent

Before 10 a.m. ET Friday, 108 stocks made new 52-week highs. Facts of Interest: UnitedHealth Group ...

The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs
26 Mar, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Highs On Thursday
25 Mar, 2021 FinancialContent

Thursday morning saw 23 companies set new 52-week highs. Noteworthy Highlights: Cisco Systems (NASDAQ:CSCO) ...

INVESTIGATION ALERT: Halper Sadeh LLP Investigates TPCO, STAY, GNMK, WIFI; Shareholders Are Encouraged to Contact the Firm
25 Mar, 2021 FinancialContent
Why Roche's $1.8 Billion Acquisition of GenMark Is a Smart Move
24 Mar, 2021 FinancialContent

GenMark appears to be a good fit for Roche's diagnostics business.

STOCK ALERT: Halper Sadeh LLP Investigates RMBL, STAY, GNMK, TPCO; Shareholders Are Encouraged to Contact the Firm
18 Mar, 2021 FinancialContent
GENMARK INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of GenMark Diagnostics - GNMK
17 Mar, 2021 FinancialContent

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of GenMark Diagnostics (NasdaqGM: GNMK) to F. Hoffmann-La Roche Ltd. Under the terms of the proposed transaction, shareholders of GenMark will receive only $24.05 in cash for each share of GenMark that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2021
17 Mar, 2021 FinancialContent

Upgrades According to Nomura Instinet, the prior rating for Noah Holdings Ltd (NYSE:NOAH) was changed from Neutral to ...

The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes
17 Mar, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy
16 Mar, 2021 FinancialContent

Roche Holding AG (OTC: RHHBY) acquired GenMark Diagnostics, Inc(NASDAQ:GNMK) in a $1.8 billion dealon Monday, the same ...

The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study
16 Mar, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

65 Biggest Movers From Yesterday
16 Mar, 2021 FinancialContent

Gainers Sigma Labs, Inc. (NASDAQ: SGLB) jumped 128.7% to close at $7.64 on Monday after the company secured a contract for an ...

Stock Upgrades: Genmark Diagnostics Shows Rising Relative Strength
16 Mar, 2021 FinancialContent

Genmark Diagnostics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Why GenMark Stock Soared Today
16 Mar, 2021 FinancialContent

A healthcare titan is acquiring the diagnostic-test maker for a hefty premium.

Best Stocks To Buy Right Now? 4 Health Care Stocks To Know
15 Mar, 2021 FinancialContent
Notable Monday Option Activity: JACK, SPG, GNMK
15 Mar, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Jack in the Box, Inc. (JACK), where a total of 4,824 contracts have traded so far, representing approximately 482,400 underlying shares..

Mid-Afternoon Market Update: Dow Rises 50 Points; Shaw Communications Shares Spike Higher
15 Mar, 2021 FinancialContent

Toward the end of trading Monday, the Dow traded up 0.15% to 32,829.24 while the NASDAQ rose 0.65% to 13,406.57. The S&P also rose, ...

GENMARK DIAGNOSTICS INVESTIGATION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP is investigating the GenMark Diagnostics acquisition by F. Hoffman La-Roche Ltd.
15 Mar, 2021 FinancialContent
12 Health Care Stocks Moving In Monday's Intraday Session
15 Mar, 2021 FinancialContent

Gainers Check-Cap (NASDAQ:CHEK) shares rose 115.68% to $3.3 during Monday's regular session. Trading volume for this ...

GENMARK ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of GNMK and Encourages Investors to Contact the Firm
15 Mar, 2021 FinancialContent
42 Stocks Moving In Monday's Mid-Day Session
15 Mar, 2021 FinancialContent

Gainers Rubius Therapeutics, Inc. (NASDAQ: RUBY) shares jumped 102.6% to $33.29 after the company reported initial clinical data ...

Mid-Day Market Update: Intec Pharma Jumps Following Merger News; HighPoint Resources Shares Plunge
15 Mar, 2021 FinancialContent

Midway through trading Monday, the Dow traded down 0.01% to 32,776.65 while the NASDAQ rose 0.31% to 13,361.69. The S&P also fell, ...

GenMark Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of GenMark Diagnostics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – GNMK
15 Mar, 2021 FinancialContent

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of GenMark Diagnostics, Inc. (NASDAQ: GNMK) to Roche is fair to GenMark shareholders. Under the terms of the merger agreement, Roche will acquire all outstanding shares of GenMark common stock for $24.05 per share in cash.

GenMark Diagnostics, Inc (GNMK) is a NASDAQ Common Stock listed in , ,

970x250